BiotechTube

HLD200 methylphenidate hydrochloride capsules + Placebo HLD200 capsules

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Attention Deficit Hyperactivity Disorder

Conditions

Attention Deficit Hyperactivity Disorder

Trial Timeline

Sep 13, 2024 → Jul 11, 2025

NCT ID
NCT06431256

About HLD200 methylphenidate hydrochloride capsules + Placebo HLD200 capsules

HLD200 methylphenidate hydrochloride capsules + Placebo HLD200 capsules is a phase 3 stage product being developed by Collegium Pharmaceutical for Attention Deficit Hyperactivity Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT06431256. Target conditions include Attention Deficit Hyperactivity Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Attention Deficit Hyperactivity Disorder were approved

Approved (20) Terminated (3) Active (0)
✅atomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Atomoxetine HydrochlorideEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Atomoxetine hydrochloride + PlaceboEli LillyApproved
✅Atomoxetine + PlaceboEli LillyApproved
✅AtomoxetineEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06431256Phase 3Terminated

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
Atomoxetine + PlaceboEli LillyPhase 2/3
38
AtomoxetineEli LillyApproved
35
Atomoxetine HydrochlorideEli LillyApproved
43
AtomoxetineEli LillyPhase 3
40
AtomoxetineEli LillyApproved
43
Atomoxetine hydrochloride + PlaceboEli LillyApproved
43
CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3
40
Donepezil hydrochloride + PlaceboEisaiPhase 3
40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)Eli LillyPhase 2/3
38
Atomoxetine + PlaceboEli LillyApproved
43
AtomoxetineEli LillyApproved
43
AtomoxetineEli LillyPre-clinical
26
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine hydrochlorideEli LillyPhase 3
40
Atomoxetine Hydrochloride + PlaceboEli LillyApproved
43
atomoxetineEli LillyPhase 3
40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/dayEli LillyPhase 3
40
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine HydrochlorideEli LillyPhase 3
40